Pressure BioSciences, Inc.

Equities

PBIO

US74112E2081

Medical Equipment, Supplies & Distribution

Delayed OTC Markets Other stock markets 08:12:54 10/06/2024 pm IST			5-day change	1st Jan Change
0.1648 ^USD	-3.40%		-19.45%	-50.06%

07/06	Pressure BioSciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
15/02	Pressure BioSciences, Inc. Completes Relocation into New Manufacturing Facility, Consolidating R&D with Expanded UltraShear Equipment Development and Contract Manufacturing	CI

Joseph Damasio Resigns from Pressure Biosciences, Inc. as Vice President of Finance and Administration, Effective from November 16, 2012

November 03, 2012 at 02:37 am IST

On November 1, 2012, Mr. Joseph Damasio informed Pressure BioSciences, Inc., that he would be resigning from his position of vice president of finance and administration, to pursue other opportunities, effective from November 16, 2012. After November 16, 2012, Mr. Damasio will provide transition services to the company to the extent that they do not interfere with his then-current employment.

Latest news about Pressure BioSciences, Inc.

Pressure BioSciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	08/06	CI
Pressure BioSciences, Inc. Completes Relocation into New Manufacturing Facility, Consolidating R&D with Expanded UltraShear Equipment Development and Contract Manufacturing	15/02	CI
Transcript : CBH International LLC, Pressure BioSciences, Inc. - M&A Call	06/02
Pressure BioSciences, Inc. completed the acquisition of CBH International LLC.	22/01	CI
Pressure BioSciences, Inc. Receives Open Order Agreement from West Coast Manufacturing Partner	18/01	CI
Pressure BioSciences, Inc. entered into a definitive agreement to acquire CBH International LLC.	11/01	CI
Pressure BioSciences' BaroFold Platform Expected to Revolutionize Biopharmaceutical Production with Help from New Computational (AI/ML) Technologies	04/01	CI
Pressure BioSciences, Inc. Announces the Publication of Pivotal Scientific Study in the Critical Field of Food Safety	12/12	CI
Pressure BioSciences and Veterans Service Team Launch UltraShear Best-in-Class Nano-CBD Topical Spray - MMA Champ Cat Zingano Now Official VST Ambassador	01/12	CI
Transcript : Pressure BioSciences, Inc., Q3 2023 Earnings Call, Nov 21, 2023	22/11
Earnings Flash (PBIO) PRESSURE BIOSCIENCES Reports Q3 Revenue $413,009	21/11	MT
Pressure BioSciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	21/11	CI
Pressure Biosciences Announces Exclusive Distribution Agreement with Bioscreen Instruments Pvt Ltd	18/23/18	CI
Pressure BioSciences' Partner Veterans Service Team Increases Existing Purchase Order by 10X for Bottles of UltraShear Nano-CBD Topical Spray, Effective Immediately	22/23/22	CI
Transcript : Pressure BioSciences, Inc., Q2 2023 Earnings Call, Aug 22, 2023	23/23/23
Earnings Flash (PBIO) PRESSURE BIOSCIENCES Posts Q2 Revenue $511,800	22/23/22	MT
Pressure BioSciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	22/23/22	CI
Transcript : Pressure BioSciences, Inc. - Special Call	17/23/17
Pressure BioSciences, Inc. Announces UltraShear Nano-CBD Roll-Out Program Enters Rapid Expansion Phase of Distribution and Partnering	17/23/17	CI
Pressure BioSciences, Inc. Announces UltraShear Processed Nano-CBD Topical Spray Distribution Agreement with Premier CA Cannabis Partner Creme de Canna	10/23/10	CI
Pressure BioSciences, Inc. Announces Agreement with Somalab International LLC for Development & Distribution of UltraShear-Enabled Nanoemulsified Health and Wellness Products	05/23/05	CI
Transcript : Pressure BioSciences, Inc. - Special Call	28/23/28
Pressure Biosciences, Inc. Announces Results from Third Round of Consumer Focus Group Testing of THC Nanoemulsion Oral Spray	27/23/27	CI
Pressure BioSciences, Inc. Partners with Veterans Service Team to Offer Exclusive Access for VST Members to a Unique, Custom-Made, UltraShear Nano-CBD & Other Products	13/23/13	CI
Transcript : Pressure BioSciences, Inc., Q1 2023 Earnings Call, May 16, 2023	17/23/17

Chart Pressure BioSciences, Inc.

Duration

Period

More charts

Company Profile

Pressure BioSciences, Inc. is engaged in providing broadly enabling, high pressure-based solutions for a range of industries, including biotechnology, pharmaceutical, nutraceutical, cosmeceutical, and agrochemical, as well as food and beverage manufacturing. The Company's enabling platform, Pressure Cycling Technology (PCT), utilizes alternating cycles of pressure to control bio-molecular interactions (such as cell lysis and biomolecule extraction) safely and reproducibly. The Company's BaroFold technology platform allows it to enter the bio-pharma contract services and GMP manufacturing equipment sector. It has also developed the scalable and pressure-based UltraShear Technology platform, which allows for the creation of stable nanoemulsions of otherwise immiscible fluids. It also allows for the preparation of homogenized, extended shelf-life or room temperature-stable low-acid liquid foods that cannot be preserved using existing non-thermal technologies.

Sector

Medical Equipment, Supplies & Distribution

Calendar

15/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
PRESSURE BIOSCIENCES, INC.	-50.06%	6.05M
ABBOTT LABORATORIES	-2.08%	187B
MEDTRONIC PLC	+0.57%	110B
BECTON, DICKINSON AND COMPANY	-2.10%	69.54B
CENCORA, INC.	+13.38%	46.37B
DEXCOM, INC.	-6.93%	46.05B
HOYA CORPORATION	+7.97%	42.54B
METTLER-TOLEDO INTERNATIONAL, INC.	+18.23%	30.72B
TERUMO CORPORATION	+17.70%	25.62B
ZIMMER BIOMET HOLDINGS, INC.	-7.55%	23.32B

Other Medical Equipment, Supplies & Distribution